Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response

Trends in Molecular Medicine

Volumn 22, Issue 4, 2016, Pages 271-273

  Themeli, Maria ^a   Sadelain, Michel ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; NOTCH RECEPTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; BURKITT LYMPHOMA; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CONTACT; CELL DIFFERENTIATION; CELL DIVISION; CELL ENGINEERING; CELL FUNCTION; CELL INTERACTION; CELLULAR DISTRIBUTION; CONCENTRATION (PARAMETERS); GENE EXPRESSION REGULATION; HUMAN; INTRACELLULAR SIGNALING; JURKAT CELL LINE; K562 CELL LINE; LIGAND BINDING; LYMPHOCYTE MIGRATION; NERVE CELL DIFFERENTIATION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN INDUCTION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TUMOR MICROENVIRONMENT; ANIMAL; CHEMISTRY; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES; SYNTHETIC BIOLOGY;

ANIMALS; CELL ENGINEERING; HUMANS; IMMUNOTHERAPY; NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; SYNTHETIC BIOLOGY; T-LYMPHOCYTES;

EID: 84959926108     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.02.009     Document Type: Short Survey

References (12)

1. Sadelain M., et al. Targeting tumours with genetically enhanced T lymphocytes. Nat. Rev. Cancer 2003, 3:35-45.
2. van der Stegen S.J., et al. The pharmacology of second-generation chimeric antigen receptors. Nat. Rev. Drug Discov. 2015, 14:499-509.
3. Sadelain M. CAR therapy: the CD19 paradigm. J. Clin. Invest. 2015, 125:3392-3400.
4. Di Stasi A., et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 2011, 365:1673-1683.
5. Kim M.S., et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J. Am. Chem. Soc. 2015, 137:2832-2835.
6. Wu C.Y., et al. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 2015, 350:aab4077.
7. Fedorov V.D., et al. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 2013, 5:215ra172.
8. Kloss C.C., et al. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 2013, 31:71-75.
9. Morsut L., et al. Engineering customized cell sensing and response behaviors using synthetic Notch receptors. Cell 2016, 164:780-791.
10. Roybal K.T., et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 2016, 164:770-779.
11. Gordon W.R., et al. Mechanical allostery: evidence for a force requirement in the proteolytic activation of Notch. Dev. Cell 2015, 33:729-736.
12. Favre D., et al. Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus. J. Virol. 2002, 76:11605-11611.